The Ras Signaling Pathway in Mammary Tumorigenesis and Metastasis

Journal of Mammary Gland Biology and Neoplasia

Volumn 6, Issue 1, 2001, Pages 101-113

  Malaney, Suzann ^a   Daly, Roger J ^a  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Breast cancer; Erks; MAP kinase; Metastasis; Ras; Tumorigenesis

Indexed keywords

HRAS PROTEIN, HUMAN; PROTEIN P21;

ANIMAL; BREAST TUMOR; EXPERIMENTAL NEOPLASM; FEMALE; HUMAN; METABOLISM; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BREAST NEOPLASMS; FEMALE; HUMANS; MAMMARY NEOPLASMS, ANIMAL; PROTO-ONCOGENE PROTEINS P21(RAS); SIGNAL TRANSDUCTION;

EID: 0035222855     PISSN: 10833021     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009572700317     Document Type: Article

References (72)

1. M. Barbacid (1987). Ras genes. Ann. Rev. Biochem. 56:779-827.
2. M. Boguski and F. McCormick (1993). Proteins regulating ras and its relatives. Nature 366:643-654.
3. L. van Aelst and C. D'Souza-Schorey (1997). Rho GTPases and signaling networks. Genes Dev. 11:2295-2322.
4. G. Reuther and C. Der (2000). The Ras branch of small GT-Pases: Ras family members don't fall far from the tree. Curr. Opinion Cell Biol. 12:157-165.
5. G. Clark, M. Kinch, T. Gilmer, K. Burridge, and C. Der (1996). Overexpression of the Ras-related TC21/R-Ras2 protein may contribute to the development of human breast cancers. Oncogene 12:169-176.
6. K. Barker and M. Crompton (1998). Ras-related TC21 is activated by mutation in a breast cancer cell line, but infrequently in breast carcinomas in vivo. Brit. J. Cancer 78:296-300.
7. T. Pawson (1995). Protein modules and signaling networks. Nature 373:573-580.
8. A. Migliaccio, M. Di Domenico, G. Castoria, A. de Falco, P. Bontempo, E. Nola, and F. Auricchio (1996). Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J. 15:1292-1300.
9. S. Campbell, R. Khosravi-Far, K. Rossman, G. Clark, and C. Der (1998). Increasing complexity of Ras signaling. Oncogene 17:1395-1413.
10. R. Seger and E. Krebs (1995). The MAPK signaling cascade. FASEB J. 9:726-735.
11. M. P. Scheid and J. R. Woodgett (2000). Phosphatidylinositol 3' kinase signaling in mammary tumorigenesis. J. Mam. Gland Biol. Neoplasia 6(1) xx-xx.
12. J. L. Bos (1989). Ras oncogenes in human cancer: A review. Cancer Res. 49:4682-4689.
13. S. Miyakis, G. Sourvinos, and D. Spandidos (1998). Differential expression and mutation of the ras family genes in human breast cancer. Biochem. Biophys. Res. Commun. 251:609-612.
14. M. Kraus, Y. Yuasa, and S. Aaronson (1984). A position 12-activated H-ras oncogene in all HS578T mammary carcinosarcoma cells but not normal mammary cells of the same patient. Proc. Natl. Acad. Sci. U.S.A. 81:5384-5388.
15. S. Kozma, M. Bogaard, K. Buser, S. Saurer, J. Bos, B. Groner, and N. Hynes (1987). The human c-Kirsten ras gene is activated by a novel mutation in codon 13 in the breast carcinoma cell line MDA-MB-231. Nucleic Acids Res. 15:5963-5971.
16. D. Watson, R. Elton, W. Jack, J. Dixon, U. Chetty, and W. Miller (1990). The H-ras oncogene product p21 and prognosis in human breast cancer. Breast Cancer Res. Treat. 17:161-169.
17. C. Dati, R. Muraca, O. Tazartes, S. Antoniotti, I. Perroteau, M. Giai, P. Cortese, P. Sismondi, G. Saglio, and M. De Bertoli (1991). c-erbB-2 and ras expression levels in breast cancer are correlated and show a co-operative association with unfavorable clinical outcome. Int. J. Cancer 47:833-838.
18. U.-J. Gohring, T. Schondorf, V. Kiecker, M. Becker, C. Kurbacher, and A. Scharl (1999). Immunohistochemical detection of H-ras protooncoprotein p21 indicates favorable prognosis in node-negative breast cancer patients. Tumor Biol. 20:173-183.
19. A. Schnelzer, D. Prechtel, U. Knaus, K. Dehne, M. Gerhard, H. Graeff, N. Harbeck, M. Schmitt, and E. Lengyel (2000). Rac1 in human breast cancer: Overexpression, mutation analysis, and characterization of a new isoform, Rac1b. Oncogene 19:3013-3020.
20. K. L. Troyer and D. C. Lee (2001). Regulation of mouse mammary gland development and tumorigenesis by the ERBB Signaling network. J. Mam. Gland Biol. Neoplasia 6(1) xx-xx.
21. J. R. Sainsbury, J. R. Farndon, G. K. Needham, A. J. Malcolm, and A. L. Harris (1987). Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet 1:1398-1402.
22. D. J. Slamon, W. Godolphin, L. A. Jones, J. A. Holt, S. G. Wong, D. E. Keith, W. J. Levin, S. G. Stuart, J. Udove, A. Ullrich, and M. F. Press (1989). Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712.
23. P. W. Janes, R. J. Daly, A. deFazio, and R. L. Sutherland (1994). Activation of the Ras signaling pathway in human breast cancer cell lines overexpressing erbB-2. Oncogene 9:3601-3608.
24. V. Papa, V. Pezzino, A. Costantino, A. Belfiore, D. Giuffrida, L. Frittitta, G. Vannelli, R. Brand, I. Goldfine, and R. Vigneri (1990). Elevated insulin receptor content in human breast cancer. J. Clin. Invest. 86:1503-1510.
25. J. Resnik, D. Riechart, K. Huey, N. Webster, and B. Seely (1998). Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer. Cancer Res. 58:1159-1164.
26. A. E. Ottenhoff-Kalff, G. Rijksen, E. A. C. M. van Beurden, A. Hennipman, A. A. Michels, and G. E. J. Staal (1992). Characterization of protein tyrosine kinases from human breast cancer: Involvement of the c-src oncogene product. Cancer Res. 52:4773-4778.
27. R. Kairouz, and R. Daly (2000). Modulation of tyrosine kinase signaling in breast cancer through altered expression of signaling intermediates. Breast Cancer Res. 2:197-202.
28. R. J. Daly, M. D. Binder, and R. L. Sutherland (1994). Overexpression of the Grb2 gene in human breast cancer cell lines. Oncogene 9:2723-2727.
29. B. Verbeek, S. Adriaansen-Slot, G. Rijksen, and T. Vroom (1997). Grb2 overexpression in nuclei and cytoplasm of human breast cells: A histochemical and biochemical study of normal and neoplastic mammary tissue specimens. J. Pathol. 183:195-203.
30. S. Yip, A. Crew, J. Gee, R. Hui, R. Blamey, J. Robertson, R. Nicholson, R. Sutherland, and R. Daly (2000). Upregulation of the protein tyrosine phosphatase SHP-1 in human breast cancer and correlation with GRB2 expression. Int. J. Cancer 88:363-368.
31. E. Y. Skolnik, A. Batzer, N. Li, C.-H. Lee, E. Lowenstein, M. Mohammadi, B. Margolis, and J. Schlessinger (1993). The function of GRB2 in linking the insulin receptor to ras signaling pathways. Science 260:1953-1955.
32. N. W. Gale, S. Kaplan, E. J. Lowenstein, J. Schlessinger, and D. Bar-Sagi (1993). Grb2 mediates the EGF-dependent activation of guanine nucleotide exchange on ras. Nature 363:88-92.
33. K. L. Suen, X. R. Bustelo, T. Pawson, and M. Barbacid (1993). Molecular cloning of the mouse grb2 gene: Differential expression of the Grb2 adaptor protein with epidermal growth factor and nerve growth factor receptors. Mol. Cell. Biol. 13:5500-5512.
34. M. Rauh, V. Blackmore, E. Andrechek, C. Tortorice, R. Daly, V. Lai, T. Pawson, R. Cardiff, P. Siegel, and W. Muller (1999). Accelerated mammary tumor development in mutant polyomavirus middle T transgenic mice expressing elevated levels of either the Shc or Grb2 adapter protein. Mol. Cell. Biol. 19:8169-8179.
35. V. Sivaraman, H. Wang, G. Nuovo, and C. Malbon (1997). Hyperexpression of mitogen-activated protein kinase in human breast cancer. J. Clin. Invest. 99:1478-1483.
36. C. Wang, A. Thor, D. Moore, Y. Zhao, R. Kerschmann, R. Stern, P. Watson, and E. Turley (1998). The overexpression of RHAMM, a hyaluronan-binding protein that regulates Ras signaling, correlates with overexpression of mitogen-activated protein kinase and is a significant parameter in breast cancer progression. Clin. Cancer Res. 4:567-576.
37. S. Redmond, E. Reichmann, R. Muller, R. Friis, B. Groner, and N. Hynes (1988). The transformation of primary and established mouse mammary epithelial cells by p21-ras is concentration dependent. Oncogene 2:259-265.
38. W. Gunzberg, B. Salmons, A. Schlaeffli, S. Moritz-Legrand, W. Jones, N. Sarkar, and R. Ullrich (1988). Expression of the oncogenes mil and ras abolishes the in vivo differentiation of mammary epithelial cells. Carcinogenesis 9:1849-1856.
39. R. Clark, M. Stampfer, R. Milley, E. O'Rourke, K. Walen, M. Kriegler, J. Kopplin, and F. McCormick (1988). Transformation of human mammary epithelial cells by oncogenic retro-viruses. Cancer Res. 48:4689-4694.
40. J. Ochieng, F. Basolo, A. Albini, A. Melchiori, H. Watanabe, J. Elliott, A. Raz, S. Parodi, and J. Russo (1991). Increased invasive, chemotactic, and locomotive abilities of c-Ha-ras-transformed human breast epithelial cells. Invasion and metastasis 11:38-47.
41. F. Ciardiello, M. Gottardis, F. Basolo, S. Pepe, N. Normanno, R. Dickson, A. Bianco, and D. Salomon (1992). Additive effects of c-erbB-2, c-Ha-ras, and transforming growth factor-alpha genes on in vitro transformation of human mammary epithelial cells. Mol. Carcinogenesis 6:43-52.
42. S. Sukumar, W. Carney, and M. Barbacid (1988). Independent molecular pathways in initiation and loss of hormone responsiveness of breast carcinomas. Science 240:524-526.
43. C. Sommers, A. Papageorge, G. Wilding, and E. Gelmann (1990). Growth properties and tumorigenesis of MCF-7 cells transfected with isogenic mutants of rasH. Cancer Res. 50:67-71.
44. D. El-Ashry, D. Miller, S. Kharbanda, M. Lippman, and F. Kern (1997). Constitutive Raf-1 kinase activity in breast cancer cells induces both estrogen-independent growth and apoptosis. Oncogene 15:423-435.
45. A. Tremblay, G. Tremblay, F. Labrie, and V. Giguere (1999). Ligand-independent recruitment of SRC-1 to estrogen receptor beta through phosphorylation of activation function AF-1. Mol. Cell 3:513-519.
46. J. Font de Mora and M. Brown (2000). AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol. Cell. Biol. 20:5041-5047.
47. A. Coutts and L. Murphy (1998). Elevated mitogen-activated protein kinase activity in estrogen-nonresponsive human breast cancer cells. Cancer Res. 58:4071-4074.
48. E. Sinn, W. Muller, P. Pattengale, I. Tepler, R. Wallace, and P. Leder (1987). Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: Synergistic action of oncogenes in vivo. Cell 49:465-475.
49. A. Andres, C. Schonenberger, B. Groner, L. Henninghausen, M. LeMeur, and P. Gerlinger (1987). Ha-ras oncogene expression directed by a milk protein gene promoter: Tissue specificity, hormonal regulation, and tumor induction in transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 84:1299-1303.
50. A. Andres, O. Bchini, B. Schubaur, B. Dolder, M. LeMeur, and P. Gerlinger (1991). H-ras induced transformation of mammary epithelium is favored by increased oncogene expression or by inhibition of mammary regression. Oncogene 6:771-779.
51. L. Nielsen, C. Discafani, M. Gurnani, and R. Tyler (1991). Histopathology of salivary and mammary gland tumors in transgenic mice expressing a human Ha-ras oncogene. Cancer Res. 51:3762-3767.
52. H. Zarbl, S. Sukumar, A. Arthur, D. Martin-Zanca, and M. Barbacid (1985). Direct mutagenesis of Ha-ras-1 oncogenes by N-nitroso-N-methylurea during initiation of mammary carcinogenesis in rats. Nature 315:382-385.
53. C. Schoenenberger, A.-C. Andres, B. Groner, M. van der Valk, M. LeMeur, and P. Gerlinger (1988). Targeted c-myc gene expression in mammary glands of transgenic mice induces mammary tumors with constitutive milk protein gene transcription. EMBO J. 7:169-175.
54. P. Tremblay, F. Pothier, T. Hoang, G. Tremblay, S. Brownstein, A. Liszaur, and P. Jolicoeur (1989). Transgenic mice carrying the mouse mammary tumor virus ras fusion gene: Distinct effects in various tissues. Mol. Cell. Biol. 9:854-859.
55. J. Irigoyen, D. Besser, and Y. Nagamine (1997). Cytoskeleton reorganization induces the urokinase-type plasminogen activator gene via the Ras/Extracellular signal-regulated kinase (ERK) signaling pathway. J. Biol. Chem. 272:1904-1909.
56. E. Lengyel, H. Wang, R. Gum, C. Simon, Y. Wang, and D. Boyd (1997). Elevated urokinase-type plasminogen activator receptor expression in a colon cancer cell line is due to a constitutively activated extracellular signal-regulated kinase-1-dependent signaling cascade. Oncogene 14:2563-2573.
57. J. Ye, R. Xu, J. Taylor-Papadimitriou, and P. Pitha (1996). Sp1 binding plays a critical role in Erb-B2- and v-ras-mediated downregulation of α2-integrin expression in human mammary epithelial cells. Mol. Cell. Biol. 16:6178-6189.
58. C. T. Guy, M. A. Webster, M. Schaller, T. J. Parson, R. D. Cardiff, and W. J. Muller (1992). Expression of the neu proto-oncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci. U.S.A. 89:10578-10582.
59. C. T. Guy, R. D. Cardiff, and W. J. Muller (1992). Induction of mammary tumors by expression of polyomavirus middle T oncogene: A transgenic mouse model for metastatic disease. Mol. Cell. Biol. 12:954-961.
60. R. Ben-Levy, H. F. Paterson, C. J. Marshall, and Y. Yarden (1994). A single autophosphorylation site confers oncogenicity to the Neu/erbB-2 receptor and enables coupling to the MAP kinase pathway. EMBO J. 13:3302-3311.
61. D. Dankort, Z. Wang, V. Blackmore, M. Moran, and W. Muller (1997). Distinct tyrosine autophosphorylation sites negatively and positively modulate neu-mediated transformation. Mol. Cell. Biol. 17:5410-5425.
62. R. Fiddes, P. Janes, S. Sivertsen, R. Sutherland, E. Musgrove, and R. Daly (1998). Inhibition of the MAP kinase cascade blocks heregulin-induced cell cycle progression in T-47D human breast cancer cells. Oncogene 16:2803-2813.
63. L. Stevenson, K. Ravichandran, and A. Frackelton (1999). She dominant negative disrupts cell cycle progression on both GO-G1 and G2-M of ErbB2-positive breast cancer cells. Cell Growth Differ. 10:61-71.
64. A. Tari, M.-C. Hung, K. Li, and G. Lopez-Berestein (1999). Growth inhibition of breast cancer cells by Grb2 downregulation is correlated with inactivation of mitogen-activated protein kinase in EGFR, but not in ErbB2, cells. Oncogene 18:1325-1332.
65. M. Holgado-Madruga, D. Emlet, D. Moscatello, A. Godwin, and A. Wong (1996). A Grb2-associated docking protein in EGF- and insulin-receptor signalling. Nature 379:560-564.
66. M. Webster, J. Hutchinson, M. Rauh, S. Muthuswamy, M. Anton, C. Tortorice, R. Cardiff, F. Graham, J. Hassell, and W. Muller (1998). Requirement for both Shc and phosphatidylinositol 3′ kinase signaling pathways in polyomavirus middle T-mediated mammary tumorigenesis. Mol. Cell. Biol. 18:2344-2359.
67. A. Cheng, T. Saxton, R. Sakai, S. Kulkarni, G. Mbamalu, W. Vogel, C. Tortorice, R. Cardiff, J. Cross, W. Muller, and T. Pawson (1998). Mammalian Grb2 regulates multiple steps in embryonic development and malignant transformation. Cell 95:793-803.
68. T. Goi, M. Shipitsin, Z. Lu, D. Foster, S. Klinz, and L. Feig (2000). An EGF receptor/Ral-GTPase signaling cascade regulates c-Src activity and substrate specificity. EMBO J. 19:623-630.
69. P. Keely, J. Westwick, I. Whitehead, C. Der, and L. Parise (1997). Cdc42 and Rac1 induce integrin-mediated cell motility and invasiveness through PI(3)K. Nature 390:632-636.
70. P. Norgaard, B. Law, H. Joseph, D. Page, Y. Shyr, D. Mays, J. Pietenpol, N. Kohl, A. Oliff, R. Coffey, H. Skovgaard Poulsen, and H. Moses (1999). Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF)α and TGFα/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis. Clin. Cancer Res. 5:35-42.
71. K. Itoh, K. Yoshioka, H. Akedo, M. Uehata, T. Ishizaki, and S. Narumiya (1999). An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nature Med. 5:221-225.
72. R. J. Daly (1999). Take your partners, please - signal diversification by the erbB family of receptor tyrosine kinases. Growth Factors 16:255-263.